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Abstract
For many biomedical applications, biodegradable and simultaneously bioactive materials are desired. These materials should at the same
time be able to support cell function and co-exist with the organism without triggering a relevant immune response.
In this work, the synthesis as well as the bioactivity evaluation of newly developed polymer soluble potato starch and composite (with
Bioactive Glass 45S5) micron-size particles are reported. An extremely interesting result is that although with different properties, both
polymer and composite particles were able to form a calcium phosphate layer at their surface, which is a clear indication of their bioactivity.
The cytotoxicity and the ability to support cell attachment and growth of the developed materials were also studied, and both polymer
and composite materials were shown to be non-cytotoxic. Preliminary results show that both types of materials were found to allow rat
bone marrow cells to attach and to proliferate on their surface and to express osteogenic markers, such as alkaline phosphatase and
osteopontin.
The obtained results indicate that the developed carriers might be used as substrates for cell culture in vitro, in order to form constructs
that might be used as a part of a tissue engineering strategy.
D 2005 Elsevier B.V. All rights reserved.
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1. Introduction
Materials for bone repair and regeneration are one of the
most studied subjects in the biomaterials field. The
particular properties of bone render it difficult to achieve a
satisfactory material that gathers all the desired character-
istics including among others mechanical properties, bone
bonding ability, and biocompatibility. In several applica-
tions, biodegradable materials are specially desired, partic-
ularly in nonload-bearing applications, where biomaterials
used as a bone substitute should be a temporary material
serving as a scaffold for bone remodelling [1–3]. This type
of material must degrade in a controlled fashion into non-
toxic products that the body can metabolise or excrete via
normal physiological mechanisms [4,5].
In vitro models both in terms of biocompatibility and
bioactivity evaluation have proven to be valuable tools for
testing and screening candidate biomaterials [1,6–8]. One
possible route to in vitro induce bioactivity into polymeric
substrates is to use autocatalytic deposition methods and
biomimetic routes in order to induce Ca-P layer formation
on the surface of the polymers [9–11]. Another strategy is
to combine polymers with bioactive materials such as
hydroxylapatite and bioactive glasses [12,13].
Since most bone implant materials are implanted into
adult bone in direct contact with bone marrow tissue, it is
advantageous to use bone marrow cell cultures from adult
rats to investigate new implant materials [14–16]. Bone
marrow cells have been reported to proliferate and differ-
entiate, to express bone cell markers, and to form
mineralised nodules in vitro [17,18]. In this work, we have
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used such type of cultures aiming at assessing if rat bone
marrow cells were capable of displaying this same
behaviour in the presence of starch and starch-bioactive
glass microparticles. In this way, by isolating and culturing
rat bone marrow cells and placing them in contact with
potential biomaterials, it is possible to gain insights on
foreseen behaviour of the material in vivo.
2. Materials and methods
2.1. Synthesis of soluble starch and soluble starch Bioactive
Glass 45S5 particles
Paselli II (PaII), a soluble potato starch chemically
modified (AVEBE, The Netherlands) was the raw material
used. The reinforcement material, Bioactive Glass 45S5
(46.1% SiO2, 24.4% Na2O, 26.9% CaO, 2.6% P2O5, mol%)
was obtained from MO-SCI (Rolla, MO, USA) and ground
before use to a particle size smaller than 16 Am.
For the synthesis of starch and composite particles,
Paselli II starch was dissolved in water together with a
crosslinking agent, trisodium trimethaphosphate (TSTP).
For the synthesis of the composite particles, 30% of the
polymer weight of BG 45S5 was mixed with the polymer
powder at this step. This solution was then placed under
constant vigorous stirring with a top stirrer, to which a
mixture of light mineral oil and sorbitan monooleate (SPAN
80)–selected as emulsifying agent–was slowly added. After
the formation of the emulsion, sodium hydroxide was added
dropwise in order to activate the crosslinking reaction,
which proceeded for 6 h. The emulsion was then destabi-
lised with a mixture of water: acetic acid (1:1) or with 100%
ethanol (in case of composite particles to prevent BG 45S5
reactions). Produced particles were collected, extensively
washed, and then freeze-dried.
2.2. Morphology
The synthesized particles were morphologically charac-
terized by light microscopy and scanning electron micros-
copy (SEM). The particles were observed and photographed
in an optical microscope with an image acquisition system
(high-resolution colour video camera and Image-Pro Plus
analysis software; Media Cybernetics, Silver Spring, Mary-
land, USA). Scanning electron microscopy (SEM) analysis
was performed on gold-coated samples in a Leica Cambridge
S-360 (Cambridge, UK), and energy dispersive spectroscopy
(EDS) was performed on carbon-coated samples.
2.3. In vitro bioactivity evaluation
PaII and PaII–30% BG particles were tested in vitro for
their bioactivity in a 0.05 M Tris hydroxymethyl amino-
methane-buffered solution complemented with electrolytes
typical for plasma (TE). The use of this solution was
described previously by Kokubo et al. [19]. PaII and PaII–
30% BG particles were immersed in TE at a ratio of 3 mg/
ml in a CO2 incubator at 37 -C. The vials were placed on
an orbital shaker at a rotational speed of 150 rpm for up
to 21 days without solution exchange. At designed time
points (1, 2, 3, 7, 10, 14, and 21 days), the samples were
removed from the shaker, the pH of the solution
measured, and the particles separated from the solution
by filtration. The particles were then dried and stored in a
desiccator until further analysis. The postimmersion so-
lutions were used to perform chemical analysis, namely for
changes in Ca, Si, and P concentrations, that were evaluated
by ICP-OES (inductively coupled plasma–optical emission
spectroscopy).
Further characterization of the immersed particles was
performed using Fourier transformed infrared attenuated
reflection (FTIR-ATR), scanning electron microscopy/
energy dispersive spectroscopy (SEM/EDS) analysis, and
X-ray diffraction (XRD) analysis.
2.4. Short-term cytotoxicity evaluation
For cytotoxicity evaluation by indirect contact with the
materials, two different tests were performed: MTT, a
viability test widely used to assess the cytotoxicity of a





Fig. 1. Light microscopy images of the synthesised particles: PaII (A) and PaII–30% BG (B). The appearance of the particles is spherical and no differences in
morphology can be attributed to the presence of BG 45S5 (original magnification, 40!).
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The cells used in this study were an immortalized cell
line of subcutaneous areolar fibroblasts from mouse
origin purchased from Collection of Cell Culture
(ECACC, UK; ref. 85011425), designated L929. The
cells were grown in monolayer systems in Dulbecco’s
modified Eagle’s medium (DMEM) (supplemented with
antibiotics and FBS) and used at low passages. The
materials were extracted in DMEM culture medium
(supplemented as described above) for 24 h at 60 rpm.
After this time period, the culture medium with the


















































Fig. 3. Si (A), Ca (B), and P (C) profiles during 21 days of immersion in TE (control). Measurements were made on control solutions (Ctrl) and solutions in
which either PaII (Pa) or PaII–30% BG (PaBG) particles were previously immersed.
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2.4.1. MTT
The MTT test is a biochemical test widely used to assess
cytotoxicity by measuring cell viability and proliferation in
a qualitative way [20,21]. This biochemical test is based in
the reduction of (3-(4,5-dimethylthiazol-2-yl)-2,4-diphenyl-
tetrazolium bromide) (which is water-soluble and has a
yellow tonality) by the cell mitochondrial enzyme succinate
dehydrogenase, yielding a purple colour salt insoluble in
water [22]. The salt absorbs at a wavelength of 570 nm and
since only living cells have the capability of metabolising
the MTT, it gives a measurement of the viable cells [22].
The procedure followed for this test was as described
previously [23]. All the materials were tested in 10
replicates for each extract for at least two independent
experiments with reproducible results. The results are
expressed as a percentage of the control (scored as 100%
viability) as meanTS.E.
2.4.2. Total protein quantification
The method that was used to quantify the total protein
uses the Micro BCA Protein Assay Reagent Kit, in which
bicinchoninic acid (BCA) is the detection reagent for a Cu
complex, which is formed when Cu2+ is reduced by proteins
in an alkaline environment [24]. The purple colour product
is due to the chelation of two molecules of BCA with one
Cu ion. This complex is water-soluble and absorbs at 562
nm, and its optical density is linearly correlated with protein
concentration [24]. The procedure was performed as
described in a previous work [23].
All the materials were tested in 10 replicates for each
extract for at least three separate experiments, with
reproducible results. The results are expressed as percentage
of the control (scored as 100% viability) as meanTS.E.
2.5. Rat bone marrow stromal cells: isolation and culture
Rat bonemarrow cells (RBMC)were isolated and cultured
according to the method described by Maniatopoulos et al.
[17]. In brief, femora of 5-week-old Wistar rats were
removed, cleaned from soft tissue, cut at the epiphyses, and
then flushed into a-MEM culture medium supplemented with
FBS, antibiotics, ascorbic acid, h-glycerophosphate, and
dexamethasone. The cells were maintained at 37 -C, 5% CO2
for 6 days, with medium change for removing debris.
Meanwhile, a pre-determined amount of PaII and PaII–
30% BG particles enough to cover the bottom of a well of a
24-well plate was weighted and placed in non-adherent cell
culture plates. The use of this particular type of culture
plates is to prevent the quantification of any response
coming from cells adhered to the well and not to the
materials. Prior to cell seeding, the materials were ethanol-
sterilised and pre-incubated for 24 h in 500 Al of culture
medium in the 24-well plates.
The cells were detached using trypsin and seeded at a
density of 5!104 cells/well. Two studies were performed—
both polymer and composite materials were cultured in two
different conditions, with culture medium supplemented
with and without dexamethasone. Dexamethasone was
used–together with ascorbic acid–as a means of inducing
the commitment of rat bone marrow cells into the
osteoblastic lineage. The absence of dexamethasone in one
set of experiments had the aim of assessing if cells cultured
on the surface of starch-based particles could commit to the
osteoblastic lineage even in the absence of dexamethasone.
The cultures were maintained for 17 days, with periodic
evaluations whenever the culture medium was changed
(every 3 days).
2.6. Total protein quantification and alkaline phosphatase
activity
Total protein quantification was performed as described
in Section 2.4.2. In each well, the culture medium was




Starch-OH + Na3P9O9                     Starch-O-P-O-Starch 
Fig. 4. Mechanism of starch crosslinking with trisodium trimethaphosphate
in sodium hydroxide aqueous (aq) solution [17].
A B 
Fig. 5. PaII particles after 21 days of immersion (A and B). Image (B): a higher magnification showing the morphology of the Ca-P layer covering the surface
of the particles.
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with PBS for total protein quantification. Then 500 Al of
PBS was added followed by 100 Al of the BCA reagent to
each well, and further incubated for 2 h. The optical
densities were measured and total protein (in Ag) was
determined using a BSA standard curve.
Alkaline phosphatase (ALP) activity was assayed by the
release of p-nitrophenol from p-nitrophenylphosphate as
described before [25].
2.7. Immunocytochemistry
The 14-day samples (control particles and particles
cultured with cells) were washed twice with 2 ml of PBS
1! (phosphate buffered saline tablets; Sigma, St. Louis,
USA) for 10 min. The samples were fixated with 0.5%
glutaraldehyde in PBS 1! (glutaraldehyde grade II 25%
aqs.; Sigma-Aldrich, St. Louis, USA) and incubated for 30
min at 37 -C. After fixation, samples were washed again
twice with PBS for 10 min.
Afterwards cells were permeabilised through the incuba-
tion with a 0.2% solution of Triton X-100 in PBS, 2 min at
room temperature, followed by a washing step, three times
with PBS for 5 min. The primary antibody used was the
mouse monoclonal antibody MPIIIB10 (DSHB, University
of Iowa, IA, USA) that was raised against a rat bone extract
fraction.
Samples were incubated with the primary antibody in a
humidified atmosphere at room temperature with a 1/100
dilution (in a 3% BSA/PBS solution) of the MPIIIB10 anti-
osteopontin antibody for 1 h. This incubation period was
followed by washings (3!) with PBS for 5 min each. For
detection of the primary antibody, a 1/100 dilution of the
secondary antibody conjugated with a fluorochrome (Alexa
Fluori 488 goat anti-mouse IgG; Molecular Probes,
Leiden, The Netherlands) was added to each lamella for 1
h at room temperature and protected from light. After the
secondary antibody incubation, the samples were again
washed with PBS (3!, 5 min each).
The ProLong\AntifadeKit montagemedium (ProLong\
Antifade Kit (P-7481), Molecular Probes, Leiden, The
Netherlands) was prepared and dropped onto the samples
and dried for 1 h, after which the samples where observed on a
fluorescence microscope with a coupled camera/image
acquisition system.
3. Results and discussion
3.1. Synthesis of polymer and composite starch and starch
Bioactive Glass 45S5
The synthesis of soluble starch PaII and PaII–30% BG
45S5 particles yielded particles with a spherical morphology
with varied sizes, up to 500 Am (Fig. 1A and B). The
presence of BG 45S5 does not seem to affect both the
morphology and the size of the particles (Fig. 1B).
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Fig. 7. Energy dispersive X-ray analysis for PaII polymeric particles (A) and PaII–30% BG 45S5 composite particles (B).
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However, scanning electron microscopy analysis (Fig. 2)
of both PaII polymer (A) and Pa–30% BG composite (B
and C) particles shows that at higher magnifications, some
differences between the polymer and composite particle
surface are evident. Regarding the morphology, composite
particles seem to be more regularly spherical than polymer
ones. The major differences are observed at the surface of
the particles, where polymeric particles seem to be
composed by small particles that were crosslinked into a
bigger network (Fig. 2A).
As for composite particles (Fig. 2B and C), the surface is
smoother compared with the one from polymer (Fig. 2A)
particles. Since the synthesis methodology is the same, these
differences can be attributed to the presence of BG 45S5 in
the composite particles.
3.2. Bioactivity evaluation
The in vitro bioactivity evaluation was based on
immersion of the particles in a fluid simulating the blood
plasma ionic composition (Tris buffer complemented with
electrolytes) up to 21 days. The results for the chemical
analysis performed as function of the immersion time are
presented in Fig. 3. Fig. 3A–C display the results of the
chemical analysis of Si, Ca, and P in immersion solution for
the analysed time points.
As can be seen in Fig. 3A, BG 45S5 was successfully
incorporated into PaII–30% BG particles, as seen by the
cumulative Si release for the immersion times. As for PaII
particles, no Si release was observed, as expected. Together
with the Si, also Ca and P concentrations in solution were
evaluated for both polymer and composite particles. The
variation of calcium in the solution (Fig. 3B) is reduced for
both PaII and PaII–30% BG particles, when comparing
with the control. This indicates that there is only a minor
withdrawal of calcium from the solution. As for phosphate
(Fig. 3C), there are differences between the two materials,
since for PaII particles, the amount of phosphate in solution
increases over time. This phenomenon might be explained
by the fact that the synthesis of these materials includes a
crosslinking step that uses a phosphate-containing com-
pound, trisodium trimethaphosphate (TSTP), as crosslink-
ing agent. These materials being biodegradable, we might
speculate that the increase in phosphate observed in
solution might be due to the scission of less strong
crosslinked starch chains, thus releasing small starch and
phosphate groups into the solution. This phosphate release
from the structure of the particles occurs via a mechanism
independent of the phosphate precipitation that is occurring










Fig. 8. FTIR spectra of PaII–30% BG 45S5 particles for 0, 14, and 21 days of immersion. (?) CfO bond; (h) P–O stretch.










Fig. 9. X-ray dispersion of Pa–30% BG particles at 0, 7, 14, and 21 days of
immersion. Main peaks are observed at 26 and 32 at 2h angle values,
although several secondary peaks are present at other values. The main
peaks are typical for HA 90432 JCPDS file.
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at the surface of the particles to form a Ca-P layer. The
crosslinking mechanism, as represented in Fig. 4, displays
the bonding between the crosslinking agent and starch
groups. This phosphate release is most probably higher
than the amount of phosphate precipitating at the particles
surface, which causes the increase in P amount in solution
observed in the Fig. 3C.
As for composite PaII–30% BG particles, there is a
progressive decrease of phosphate in the solution, indicating
that this ion was being precipitated at the surface of the
particles, giving origin to a bioactive Ca-P layer (Fig. 3C).
Further analysis by SEM (Figs. 5 and 6) shows that, in
fact, both polymer and composite particles display at their
surface a deposited Ca-P layer, although more clearly in the
composite particles.
For PaII particles, there is a layer of Ca-P deposited at the
surface, confirmed by EDS (Fig. 7A), and P seems to be
present in higher amounts at the particles’ surface than Ca.
This result can be explained by the presence of P in the
starch network, which does not allow to determine the Ca-P
ratio of the layer. Previous works have shown that materials
with terminal P groups are able to form an apatite layer
when soaked in SBF without induction time and at a higher
growth rate than for other groups [26]. In the present work,
the presence of phosphate in the starch particle network
might induce the Ca deposition and consequent Ca-P
formation at the surface of the particles, since it is known
that the apatite induction is facilitated by increasing
concentrations of either Ca or P [27].
As for the composite particles (Fig. 7B), EDS analysis























Fig. 11. Total protein quantification for Pa and Pa–30% BG 45S5 particles.
The values shown are presented as a percentage of the control (cells
cultured with culture medium, scored 100%) and, for both materials, the
values are above 89%. No statistically significant differences are observed























Fig. 12. MTT test for Pa and Pa–30% BG 45S5 particles. The values for
both materials are presented as a function of the control (cells cultured with
culture medium, scored 100%). Both materials present values above 87%.



















Pa W Pa W/O PaBG W PaBG W/O
Fig. 13. Total protein content for 17 days of culture. Pa W—polymeric
particles cultured with rat bone marrow cells with dexamethasone in culture
medium; Pa W/O—polymeric particles cultured with rat bone marrow cells
without dexamethasone in culture medium; PaBG W—composite particles
cultured with rat bone marrow cells with dexamethasone in culture
medium; PaBG W/O—composite particles cultured with rat bone marrow
cells without dexamethasone in culture medium.







Fig. 10. X-ray dispersion of PaII particles at 0, 10, 14, and 21 days of
immersion. HA peaks are observed at 32- and 46-. *Material peak; (?)
major peaks appearing at 10, 14, and 21 days of immersion.
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surface of the particles, which is already visible at 7 days of
immersion (Fig. 6B, SEM image), confirming the stronger
bioactive character of the composite particles.
FTIR analysis of PaII–30% BG 45S5 particles (Fig. 8)
reveals differences in the spectra of non-immersed particles
(0 days of immersion) and after 21 days of immersion. The
enhancement of the intensity of bands at 1100–1050 cm"1,
which correspond to the P–O stretch, as well as of the CfO
bond at 1740 cm"1, is visible.
The nature of this Ca-P layer regarding its crystallinity by
X-ray dispersion, as presented in Fig. 9, was also investigated.
By comparison with the 90432 Hydroxylapatite JCPDS
standard, it is possible to observe that Pa–30% BG particles
after 7 days of immersion already present one of the HA
main peaks. It is known that the crystallization of insoluble
salts involves the formation of metastable precursor phases
[26], so with increasing immersion time, the layer of Ca-P is
growing and rearranging, and at 14 days, other typical HA
peaks are visible that, at 21 days, correspond with a great
number of less intense peaks present in the HA 90432
standard.
For PaII particles, the XRD pattern reveals that the layer
of Ca-P is growing with time, by the disappearance of the
material peak (*) and the appearance of crystalline peaks at
27-, 32-, 46-, and 57- (?) (Fig. 10).
3.3. Short-term cytotoxicity
The results for the short-term cytotoxicity evaluation are
presented in Figs. 11 (total protein) and 12 (MTT). The
results are presented as percentages of the control both for
MTT and total protein, meaning that the values obtained are
in comparison with the 100% proliferation attributed to the
control.
As it can be seen, both polymer and composite materials
present total protein values close to the one from the control.
The results obtained for both materials are above 89%,
which is a good indication of their clearly non-cytotoxic
behaviour.
This result is well correlated with the MTT results, in
which both materials present viability percentages above
87% (Fig. 12). Some difference is observed between the
results for the polymer and composite materials, and the t
test was performed to assess if these differences were
significant. The result of the t test shows that no significant
differences are found between the two materials ( p>0.05).
3.4. Total protein and ALP quantification
Fig. 13 displays the evolution of the protein content
during 17 days of culture of the particles with rat bone
marrow cells.
It is visible that cells are able to adhere to the particle
surface, and that protein content reaches a steady state after
7 days of culture, which may indicate that cells are
differentiated, since proliferation and differentiation are
described as uncoupled processes. Regarding alkaline
phosphatase activity, Fig. 14 shows its tendency after
normalisation for the total protein content. For composite
particles, the ALP highest activity is observed at day 7 of
culture with particles; as for polymeric particles, this peak is
reached after 14 days of culture. This may indicate that the
presence of BG 45S5 might influence the fate of these cells
earlier than polymeric materials.
3.5. Immunocytochemistry
As for the assessment of osteopontin expression of rat























g) Pa W Pa W/O PaBG W PaBG W/O
Fig. 14. Alkaline phosphatase activity per protein content. Pa W—
polymeric particles cultured with rat bone marrow cells with dexametha-
sone in culture medium; Pa W/O—polymeric particles cultured with rat
bone marrow cells without dexamethasone in culture medium; PaBG W—
composite particles cultured with rat bone marrow cells with dexametha-
sone in culture medium; PaBG W/O—composite particles cultured with rat
bone marrow cells without dexamethasone in culture medium.
A      B                      C
Fig. 15. Immunocytochemistry for osteopontin in PaII particles after 14 days of culture. (A) PaII particles’ autofluorescence; (B) control, PaII particles (without
cells) treated with anti-osteopontin antibody; (C) PaII particles cultured with rat bone marrow cells treated with osteopontin antibody. For both conditions–
presence and absence of dexamethasone–(A), (B), and (C) were identical; for this reason, only one image per condition is shown.
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PaII–30% BG particles, with or without dexamethasone
supplemented to the culture medium, the results are
observed in Figs. 15 and 16.
The results for PaII particles after 14 days in culture with
rat bone marrow cells clearly show that osteopontin is being
expressed, which indicates that cells have adhered to the
materials and that the cells were being able to express bone
markers. Another interesting result it that we found no
differences in osteopontin detection between cultures with
and without dexamethasone. It could be speculated that this
result might be due to the influence of the materials on the
rat bone marrow cells’ fate, which would lead to a
commitment of the cells to the osteogenic lineage regardless
of the presence of dexamethasone. However, to confirm this
hypothesis, further studies regarding other osteogenic
markers, namely osteonectin, osteocalcin, collagen I, and
runx-2/cbfa-1 expression, must be performed.
As for PaII–30% BG particles, although both their
autofluorescence and control show some staining, which is
due to the presence of BG 45S5, there is a considerable
difference in the fluorescence of the particles cultured with
rat bone marrow cells, allowing to state that osteopontin is
being expressed. As already seen for PaII particles, again no
differences were found between culture conditions (absence
or presence of dexamethasone). For this type of particles,
the presence of BG 45S5 might play a role in cell dif-
ferentiation, since it is known from the literature [28,29] that
this type of bioactive glass is capable of enhancing cell
differentiation. However, further studies must be performed
to assess the validity of this hypothesis.
4. Conclusions
It is believed that there is a correlation between the in
vitro bioactivity of a material and its ability to bond to bone.
In this way, immersion of the materials in a fluid simulating
body ionic composition and the eventual formation of a
calcium phosphate layer at the surface of the materials
denote a possible in vivo bioactive behaviour. In this work,
both polymer (PaII) particles and composite (PaII–30%
BG) particles were shown to form in vitro an apatite-like
Ca-P layer at their surface, which was analysed and shown
to have a different nature in both materials.
Short-term cytotoxicity testing shows that cells cultured
with both polymer and composite leachables remain clearly
viable. Preliminary studies on the ability of these particles to
support attachment and growth of undifferentiated rat bone
marrow cells have shown that cells do adhere to the
materials, and that they express osteopontin both in the
presence or absence of dexamethasone in the culture
medium.
These results constitute the basis of further studies
involving these materials and primary cultures of bone
marrow cells, both in standard cell culture conditions and in
an HARV (high aspect ratio vessel) bioreactor, where other
osteoblastic markers will be evaluated both by biochemical
tests and gene expression profiles, in order to establish
differences between both conditions. The aim is to move to
use these particles as carriers for cells, forming tissue
engineering constructs in appropriate bioreactor culture
conditions.
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